THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Regulators outline actions to oversee drug firms' claims

FDA, SEC would share information

By Ross Kerber
Globe Staff / February 6, 2004

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

  • E-mail|
  • Print|
  • Reprints|
  • |
Text size +

Drug and securities regulators in Washington yesterday outlined steps to ensure companies tell the truth about their dealings with the government, following complaints of improper disclosure by ImClone Systems Inc. and other biotechnology companies. (Full Article: 587 Words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $4.95 1 Article
  • $9.95 4 Articles
  • $99.95 Unlimited